02.02.2018

Oncoinvent selected to receive BIA funding from the Research Council of Norway

Press Release 02.2018: Oncoinvent is pleased to announce today that Oncoinvent has been selected to receive BIA project funding from the Research Council of Norway to help develop its lead product Radspherin®.

Download

BIA Call Results
The Programme Board/Expert Committee for BIA has awarded funding to forty-six project(s) from among the one hundred and sixty grant applications submitted under the call for proposals with a deadline of 11.10.2017. A total of NOK 483 million was allocated to the call.

Oncoinvent will now enter into contract negotiations with representatives from the Research Council to conclude the details of the BIA project including the allocation of funds, project milestones and timelines. The company will announce the details of the BIA grant once the contract has been signed.

About BIA
The Programme for User-driven Research-based Innovation (BIA) promotes the capacity and willingness of Norwegian trade and industry to innovate by providing support for R&D projects based on companies’ own strategies and challenges, independent of field or topic. The BIA programme comprises an open competitive arena for grants to Innovation Projects for the Industrial Sector, where the key criteria for awarding funding are research content, level of innovation, potential for value creation, and relevance and benefit to society. The programme is the Research Council of Norway’s primary instrument for ensuring that funding is available to all segments of Norwegian trade and industry seeking to become more innovative, competitive and internationally oriented through R&D. The BIA programme coordinates its activities with the SkatteFUNN tax incentive scheme and other programmes and instruments targeted towards R&D-based innovation within and outside the Research Council.

About Radspherin®
Radspherin® is a novel alpha-emitting radioactive microsphere designed for treatment of metastatic cancers in body cavities. The radium-224 based therapeutic, Radspherin® has shown strong and consistent anticancer activity at doses being essentially non-toxic in preclinical studies. It is anticipated that the product can potentially treat several forms of metastatic cancer. The first clinical indication for Radspherin® will be treatment of peritoneal carcinomatosis originating from ovarian cancer. Peritoneal carcinomatosis is one of the most serious complications of gastrointestinal and gynecological malignancies.

About Oncoinvent
Oncoinvent AS is a privately held Norwegian company based in Oslo, Norway. The company is committed to developing new innovative products to provide better treatment options to cancer patients.

The company's founders started Oncoinvent in 2010 with a view to designing better cancer treatments by applying known physical and chemical principles of selected novel materials in new ways to maximize their medical benefit while minimizing potential safety concerns. This approach has allowed the company to develop a rich development pipeline and to explore multiple technological avenues before selecting a lead product candidate for preclinical testing.

For further information, please contact:
Jan A. Alfheim, Chief Executive Officer
Cell: +47 46 44 00 45
Email: Alfheim@oncoinvent.com

IR enquiries:
Ole Peter Nordby, Chief Financial Officer
Cell: +47 41 28 71 79
Email: nordby@oncoinvent.com

Read more

Less...

01.31.2018

New Radspherin® data published

Press Release 01.2018: Oncoinvent is pleased to announce today that Oncoinvent researchers have published data demonstrating the efficacy of the Radspherin® in two separate models of peritoneal carcinomatosis originating from ovarian cancer cell lines in the journal Translational Oncology.

Download

Summary of findings
In both models, intraperitoneal treatment with Radspherin® gave significant antitumor effect with either considerably reduced tumor volume or a survival benefit. An advantageous discovery was that only a few kilobecquerels were needed to yield therapeutic effects. The treatment was well tolerated up to a dose of 1000 kBq/kg with no signs of acute or subacute toxicity observed. Intraperitoneal α-therapy with Radspherin® demonstrated a  significant potential for treatment of peritoneal micrometastases in ovarian carcinoma.

A free access copy of the article can be obtained through the science direct website: https://doi.org/10.1016/j.tranon.2017.12.011

About Radspherin®
Radspherin® is a novel alpha-emitting radioactive microsphere designed for treatment of metastatic cancers in body cavities. The radium-224 based therapeutic, Radspherin®  has shown strong and consistent anticancer activity at doses being essentially non-toxic in preclinical studies. It is anticipated that the product can potentially treat several forms of metastatic cancer. The first clinical indication for Radspherin® will be treatment of peritoneal carcinomatosis originating from ovarian cancer. Peritoneal carcinomatosis is one of the most serious complications of gastrointestinal and gynecological malignancies. 

About Oncoinvent
Oncoinvent AS is a privately held Norwegian company based in Oslo, Norway. The company is committed to developing new innovative products to provide better treatment options to cancer patients.

The company's founders started Oncoinvent in 2010 with a view to designing better cancer treatments by applying known physical and chemical principles of selected novel materials in new ways to maximize their medical benefit while minimizing potential safety concerns. This approach has allowed the company to develop a rich development pipeline and to explore multiple technological avenues before selecting a lead product candidate for preclinical testing.

For further information, please contact:
Jan A. Alfheim, Chief Executive Officer
Cell: +47 46 44 00 45
Email: Alfheim@oncoinvent.com

IR enquiries:
Ole Peter Nordby, Chief Financial Officer 
Cell: +47 41 28 71 79 
Email: nordby@oncoinvent.com

Read more

Less...

12.13.2017

Opening of the Radspherin® Production and Laboratory Facility

Press Release 08.2017: Oncoinvent held an opening ceremony for its new production and lab facilities today. A total of 40 guests attended the opening.

Download

The new production facility contains a dedicated Grade B clean room, two Category B type isotope production suites, a quality control laboratory, and packaging area that will support qualified operations for manufacturing, analytical control, packaging and labelling of Radspherin® for upcoming preclinical and clinical studies.

Jan A. Alfheim, Oncoinvent’s CEO commented: “This event marks a highlight in a year that has seen tremendous growth in  the company.  The opening of our new laboratory and production facilities represents a significant achievement for the company and will enable the company to move Radspherin® rapidly into the next phase of development in 2018.”    

About Radspherin®
Radspherin® is a novel alpha-emitting radioactive microsphere designed for treatment of metastatic cancers in body cavities. The radium based therapeutic, Radspherin® has shown strong and consistent anticancer activity at doses being essentially non-toxic in preclinical studies. It is anticipated that the product can potentially treat several forms of metastatic cancer. The first clinical indication for Radspherin® will be treatment of peritoneal carcinomatosis originating from ovarian cancer. Peritoneal carcinomatosis is one of the most serious complications of gastrointestinal and gynecological malignancies. 

About Oncoinvent
Oncoinvent AS is a privately held Norwegian company based in Oslo, Norway. The company is committed to developing new innovative products to provide better treatment options to cancer patients.

The company's founders started Oncoinvent in 2010 with a view to designing better cancer treatments by applying known physical and chemical principles of selected novel materials in new ways to maximize their medical benefit while minimizing potential safety concerns. This approach has allowed the company to develop a rich development pipeline and to explore multiple technological avenues before selecting a lead product candidate for preclinical testing.

For further information, please contact:
Jan A. Alfheim, Chief Executive Officer
Cell: +47 46 44 00 45
Email: Alfheim@oncoinvent.com
IR enquiries:
Ole Peter Nordby, Chief Financial Officer 
Cell: +47 41 28 71 79 
Email: nordby@oncoinvent.com
 

Read more

Less...

11.15.2017

Radspherin® EU patent and OI-3 antibody US patent issued

Press Release: Oncoinvent announced today that European Patent 3111959 entitled ”Radiotherapeutic particles and suspensions” has issued. This patent provides patent protection for the company’s lead product candidate Radspherin® in Europe. The patent relates to a particle or pharmaceutical composition comprising one or more particles, or a suspension of same or different particles comprising a degradable compound and an alpha emitting radionuclide and/or a radionuclide generating alpha emitting daughter. The particles are beneficial for use in the treatment of cancer.

Download

The company further announced that US Patent 9,782,500 entitled “Monoclonal Antibody and Derivatives” has issued.  The patent relates to Oncoinvent’s novel anti-CD146 antibody, OI-3 and derivatives that can be used for therapy and imaging, diagnosis and immunostaining.  CD146 is an antigen that is up-regulated in numerous cancers including melanoma, prostate cancer, breast cancer and lung cancer.

Jan A. Alfheim, Oncoinvent’s CEO commented: “This is significant milestone in both the development of our lead product candidate, Radspherin® as well as development of our pipeline of follow on product candidates behind Radspherin®.   With the Radspherin® patent issuing in Europe we have secured protection of Radspherin® until 2035 in most of the major future markets for the product.” Alfheim continued, “The issuance of our OI-3 antibody patent in the USA provides Oncoinvent a patent protection of potential novel OI-3 cancer  
immunotherapies, as well as potential radioimmunotherapies based on a combination our Ra-224 radioisotope technology platform and the OI-3 antibody.” 

About Radspherin®
Radspherin® is a novel alpha-emitting radioactive microsphere designed for treatment of metastatic cancers in body cavities. The radium based therapeutic, Radspherin® has shown strong and consistent anticancer activity at doses being essentially non-toxic in preclinical studies. It is anticipated that the product can potentially treat several forms of metastatic cancer. The first clinical indication for Radspherin® will be treatment of peritoneal carcinomatosis originating from ovarian cancer. Peritoneal carcinomatosis is one of the most serious complications of gastrointestinal and gynecological malignancies. 

About Oncoinvent
Oncoinvent AS is a privately held Norwegian company based in Oslo, Norway. The company is committed to developing new innovative products to provide better treatment options to cancer patients.

The company's founders started Oncoinvent in 2010 with a view to designing better cancer treatments by applying known physical and chemical principles of selected novel materials in new ways to maximize their medical benefit while minimizing potential safety concerns. This approach has allowed the company to develop a rich development pipeline and to explore multiple technological avenues before selecting a lead product candidate for preclinical testing.

For further information, please contact:
Jan A. Alfheim, Chief Executive Officer
Cell: +47 46 44 00 45
Email: Alfheim@oncoinvent.com

IR enquiries:
Ole Peter Nordby, Chief Financial Officer 
Cell: +47 41 28 71 79 
Email: nordby@oncoinvent.com

Read more

Less...

10.23.2017

Oncoinvent presents Radspherin® preclinical data at 30th Annual Congress of the European Association of Nuclear Medicine (EANM)

Press Release 06.2017

  • Work presented indicates that, with certain precautions, 224Ra based biomedical products can be used in a safe manner for the hospital staff and patients.
  • In vivo studies show that 224Ra-labeled CaCO3 microparticles could be safely administered in mice at therapeutically relevant doses and with a high degree of intraperitoneal retention.
  • The novel α-emitting microparticles have properties that make them a promising new modality for intracavitary cancer therapy.

Download

Oslo 23 October 2017

Oncoinvent, a preclinical stage company committed to developing new innovative products to provide better treatment options to cancer patients, announced new data from the ongoing preclinical development of Radspherin®.

These data were provided in oral presentations given by research scientists Elisa Napoli and Sara Westrøm during the Sunday morning session of the scientific program at the European Association of Nuclear Medicine (EANM) in Vienna, Austria.

Abstracts of the presentations are listed below.

Re-localization of 212Pb from 224Ra sources due to thoron (220Rn) diffusion

E. Napoli1,2,3, S. Westrøm1,2,3, T. B. Bønsdorff3, Ø. S. Bruland1,2,3, R. H. Larsen4;

1 University of Oslo, Oslo, NORWAY, 2 The Norwegian Radium Hospital, Oslo, NORWAY, 3 Oncoinvent AS, Oslo, NORWAY, 4 Sciencons AS, Oslo, NORWAY.

Aim: Alpha-particle-emitting radium nuclides have been the subject of considerable biomedical research due to their highly localized effect. Radium-224, with a convenient half-life of 3.6 days, has promising properties for use against micro-metastatic disease. The aim of this work was to investigate the radiation safety aspects with a focus on thoron (220Rn) diffusion from its parent nuclide 224Ra. Thoron diffusion was studied for 224Ra either as free cation in solution or bound to biocompatible calcium carbonate (CaCO3) microparticles. Materials and Methods: Radium-224 was extracted from 228Th immobilized on Actinide Resin in 1 M hydrochloric acid (HCl). The acid was evaporated and the residue reconstituted in 0.1 M HCl and subsequently neutralized with ammonium acetate. The CaCO3 microparticles were prepared by precipitation of the combination of sodium carbonate and calcium chloride solutions. Thereafter, the microparticles were radiolabeled by mixing with 224Ra solution at neutral pH. Re-localization of 212Pb, due to thoron escape from solutions of free 224Ra and 224Ra-CaCO3 microparticle suspensions, was studied in various experimental setups. The potential leakage of thoron was examined from frequently used containers such as: 1.5/5 ml Eppendorf tubes, 6 ml Chromacol head-space injection vials capped and crimped with a stopper and different size of syringes. In addition, the influence of liquid volume on thoron diffusion into air was studied from open vials. Due to its short physical half-life of 56 s, thoron diffusion into the air was evaluated by measuring its decay product 212Pb, which has a longer half-life of 10.64 h. Gamma-counting was performed with the Hidex Automatic Gamma Counter (Turku, Finland). Results: The results indicate that free cationic 224Ra solutions and 224Ra-CaCO3 microparticle suspensions can be used in a safe manner, without significant leakage of thoron, when contained in vials or syringes. The data shows that at very low volumes i.e. 10-100 μl, there is significant diffusion of thoron from free cationic 224Ra solutions into air from open vials. Less diffusion from open vials was observed with 224Ra-CaCO3 suspensions. Diffusion from 10 μl volumes was between 70% and 95% less for 224Ra-CaCO3 in comparison with free cationic 224Ra solutions. Conclusion: When considering the low expected activity level needed for a therapeutic dosing, the current work indicates that, with certain precautions, 224Ra based biomedical products can be used in a safe manner for the hospital staff and patients.

Novel Intracavitary α-Therapeutic Based on Calcium Carbonate Microparticles As Carriers for 224Ra: Biodistribution and Toxicity in Mice

S. Westrøm1,2,3, T. B. Bønsdorff3, M. M. Malenge3, Ø. S. Bruland1,2,3, R. H. Larsen4,

1 University of Oslo, Oslo, NORWAY, 2 The Norwegian Radium Hospital, Oslo University Hospital, Oslo, NORWAY, 3 Oncoinvent AS, Oslo, NORWAY, 4 Sciencons AS, Oslo, NORWAY.

Aim: Peritoneal carcinomatosis occurs when cancer cells from a primary tumor in an adjacent organ migrate into the peritoneal cavity and cause micrometastases. Intraperitoneal radiation therapy with β-emitting 32P-colloid was previously used in treatment of ovarian cancer. It was shown to be as effective as adjuvant cisplatin, but resulted in higher incidence of late bowel complications, most likely caused by the several millimeters range of 32P-electrons. Our aim was to design an intracavitary treatment for peritoneal carcinomatosis with highly localized effect to minimize risk of irradiation of surrounding normal tissues. We have developed a novel therapeutic based on CaCO3 microparticles as carriers for the α-emitter 224Ra, a nuclide which emits four α-particles during its decay and has considerably shorter range than 32P. Here, the preparation of the product is presented along with evaluation of tissue distribution and toxicity in mice. Materials and Methods: CaCO3 microparticles with median diameters from 2-20 μm were prepared by spontaneous precipitation and radiolabeled by co-precipitation of 224Ra on the particle surface. The labeling yield was determined and retention of 224Ra on the microparticles was investigated in vitro. Biodistribution after intraperitoneal administration of the radiolabeled microparticles was studied in immunodeficient athymic nude mice and compared with that of free 224Ra. Toxicity of the 224Ra-labeled CaCO3 microparticles was evaluated in immunocompetent BALB/c mice. Results: Radiolabeling of the CaCO3 microparticles was successful and resulted in high yield. Experiments also showed that 224Ra was well retained on the microparticles for several days in vitro. Because of the bone-seeking capacity of 224Ra, the stability of the radiolabeled particles in vivo could be determined from the uptake of 224Ra in mice femurs. A fundamental shift in tissue radiation exposure was observed when free 224Ra was compared with 224Ra-labeled CaCO3 microparticles. The femur uptake of 224Ra was significantly reduced and radioactivity on intraperitoneal tissues and surfaces was substantially increased after administration of 224Ra-labeled CaCO3 microparticles. In immunocompetent mice, doses up to 1000 kBq/kg of 224Ra-labeled microparticles were well-tolerated and no clinical signs of toxicity were observed. Conclusion: Efficient 224Ra-labeling of the CaCO3 microparticles was achieved with high retention of the radionuclide by the particles in vitro. The in vivo studies show that 224Ra-labeled CaCO3 microparticles could be safely administered in mice at therapeutically relevant doses and with a high degree of intraperitoneal retention. In conclusion, the novel α-emitting microparticles have properties that make them a promising new modality for intracavitary cancer therapy.

About Radspherin®
Radspherin® is a novel alpha-emitting radioactive microsphere designed for treatment of metastatic cancers in body cavities. The radium based therapeutic, Radspherin® has shown strong and consistent anticancer activity without any signs of product related toxicity in preclinical studies. It is anticipated that the product can potentially treat several forms of metastatic cancer. The first clinical indication for Radspherin® will be treatment of peritoneal carcinomatosis. Peritoneal carcinomatosis is one of the most serious complications of gastrointestinal and gynecological malignancies.

About Oncoinvent
Oncoinvent AS is a privately held Norwegian company based in Oslo, Norway. The company is committed to developing new innovative products to provide better treatment options to cancer patients.

The company's founders started Oncoinvent in 2010 with a view to designing better cancer treatments by applying known physical and chemical principles of selected materials in new ways to maximize their medical benefit while minimizing potential safety concerns. This approach has allowed the company to develop a rich development pipeline and to explore multiple technological avenues before selecting a lead product candidate for preclinical testing.

The company is currently in late stage preclinical testing with its lead product candidate Radspherin®.

 

For further information, please contact:
Jan A. Alfheim, Chief Executive Officer
Cell: +47 46 44 00 45
Email: alfheim@oncoinvent.com

IR enquiries:
Ole Peter Nordby, Chief Financial Officer
Cell: +47 41 28 71 79
Email: nordby@oncoinvent.com

Read more

Less...

05.16.2017

Oncoinvent: A novel method for making 212Pb-labeled monoclonal antibodies using a novel 224Ra-based generator solution

Press Release 05.2017: Oncoinvent researchers collaborate to develop a system to generate alpha-particle releasing radioimmunoconjugates that may be simpler and less time-consuming compared with current established methods used in clinical trials.

Download

Oslo 16. May 2017

Oncoinvent is pleased to announce today that the results of a collaboration between Oncoinvent and Sciencons researchers have been published in the Journal of Nuclear Medicine and Biology.

Alpha-particles have the potential to kill tumor cells very effectively and selectively. The radioisotope 212Pb, which causes the release of alpha-particle, has a half-life of 10.6 h which imposes time constraints to its practical application as a radioimmunoconjugate for cancer therapy.  The focus of the published research was to determine whether a rapid, efficient, and reliable production and purification procedure for generating a 212Pb based radioimmunoconjugate could be developed.

Key Conclusion:
The current work demonstrates the feasibility of using a 224Ra solution as a shippable generator solution for producing 212Pb-based radioimmunoconjugates, which may be easier to execute and less time-consuming for the end user in comparison with existing ion exchange based methods. 

A free access copy of the article can be obtained through the online version of the journal: http://www.sciencedirect.com/science/journal/09698051
 
About Oncoinvent
Oncoinvent AS is a privately held Norwegian company based in Oslo, Norway. The company is committed to developing new innovative products to provide better treatment options to cancer patients.

The company's founders started Oncoinvent in 2010 with a view to designing better cancer treatments by applying known physical and chemical principles of selected novel materials in new ways to maximize their medical benefit while minimizing potential safety concerns. This approach has allowed the company to develop a rich development pipeline and to explore multiple technological avenues before selecting a lead product candidate for preclinical testing. 
The company is currently in late stage preclinical testing with its lead product candidate Radspherin®.

For further information, please contact:
Jan A. Alfheim, Chief Executive Officer
Cell: +47 46 44 00 45
Email: alfheim@oncoinvent.com

IR enquiries:
Ole Peter Nordby, Chief Financial Officer 
Cell: +47 41 28 71 79 
Email: nordby@oncoinvent.com
 

Read more

Less...

05.12.2017

Oncoinvent Strengthens Management and Research Teams

Press Release 04.2017: Key positions to assist in the development and commercialization of Radspherin® have been filled, bringing valuable expertise and experience to the company

Download

Oncoinvent is pleased to announce today that the following people will be joining the Oncoinvent team:

Kristine Lofthus started the 2 May as Head of Quality Assurance.  Kristine comes to Oncoinvent from the Institute for Energy Technology (IFE) where she has worked as QA and QP responsible for the release of radiopharmaceuticals and for quality systems for the past five years.  Prior to working at IFE, she was Head of the Manufacturing Department at the Oslo University Hospital Pharmacy. Kristine Lofthus has a cand.pharm. from the University of Oslo and a post-graduate degree in radiopharmacy.

Kristin Fure started the 2 May as Production Engineer responsible for production of Ra224 and Radspherin®.  Kristin also comes to Oncoinvent from the Institute for Energy Technology (IFE).  Kristin is a Research Scientist that has seventeen years’ experience in the manufacturing of radioisotopes.  Kristin graduated with a cand. scient. in Nuclear Chemistry from the University of Oslo.

Ole Peter Nordby who has been acting as Oncoinvent’s interim CFO has been appointed Chief Financial Officer as of May 2. Ole Peter has more than fifteen years in positions as portfolio manager, investment director and financial analyst at several funds and investment companies. Through the main part of his career as fund manager and analyst he has been occupied with listed Nordic companies in the Life Science sector.  He holds a MBA from the Norwegian Business School BI and is a Certified European Financial Analyst (CEFA).

Kari Skinnemoen has accepted the position of Head of Regulatory Affairs and will be starting 1 June. Kari has thirty-seven years’ experience within development and registration of new products in the pharmaceutical and medical device industry, including twenty-eight years’ experience in global regulatory affairs, most recently at Alere Technologies AS. She has also held managing positions within Quality Assurance and R&D. Kari holds a cand.real. degree in Organic Chemistry from the University of Oslo.

“We are very pleased that we have been able to attract such qualified and experienced people to the Oncoinvent team. Their addition will greatly help the company in the commercialization of Radspherin® and the development of the company” said Jan A. Alfheim, Oncoinvent’s CEO. 

About Radspherin®
Radspherin® is a novel alpha-emitting radioactive microsphere designed for treatment of metastatic cancers in body cavities. The radium based therapeutic, Radspherin® has shown strong and consistent anticancer activity without any signs of product related toxicity in preclinical studies. It is anticipated that the product can potentially treat several forms of metastatic cancer. The first clinical indication for Radspherin® will be treatment of peritoneal carcinomatosis originating from ovarian cancer. Peritoneal carcinomatosis is one of the most serious complications of gastrointestinal and gynecological malignancies. 

About Oncoinvent
Oncoinvent AS is a privately held Norwegian company based in Oslo, Norway. The company is committed to developing new innovative products to provide better treatment options to cancer patients.
The company's founders started Oncoinvent in 2010 with a view to designing better cancer treatments by applying known physical and chemical principles of selected novel materials in new ways to maximize their medical benefit while minimizing potential safety concerns. This approach has allowed the company to develop a rich development pipeline and to explore multiple technological avenues before selecting a lead product candidate for preclinical testing.

For further information, please contact:
Jan A. Alfheim, Chief Executive Officer
Cell: +47 46 44 00 45
Email: alfheim@oncoinvent.com

IR enquiries:
Ole Peter Nordby, Chief Financial Officer 
Cell: +47 41 28 71 79 
Email: nordby@oncoinvent.com
 

Read more

Less...

02.09.2017

Oncoinvent closes $ 25 Million Private Placement

Press Release 03.2017: Financing will support development of Radspherin®, a novel radiotherapeutic treatment for peritoneal carcinomatosis

Download

Oncoinvent announced today the closing of a 210 MNOK (approx. 25 MUSD) private placement of ordinary shares.  Large privately owned investment companies joining the Company as new investors include Geveran Trading Co. Ltd., Canica AS, CGS Holding AS, Helene Sundt AS and Must Invest AS.  Oncoinvent AS is developing therapeutics to combat various cancers based on delivery of tumour-cell killing doses of radiation and/or immunotargeting of tumor cells.

"We are pleased at the response that we have received from the investment community regarding our private placement.  The round was heavily oversubscribed.  With this financing round we now have, in addition to the new funding, a shareholder base in the company that will enable Oncoinvent to bring Radspherin® to a clinical proof of concept." said Jan A. Alfheim, Oncoinvent’s CEO. 


About Radspherin®
Radspherin® is a novel alpha-emitting radioactive microsphere designed for treatment of metastatic cancers in body cavities. The radium based therapeutic, Radspherin® has shown strong and consistent anticancer activity without any visible signs of product related toxicity in preclinical studies. It is anticipated that the product can potentially treat several forms of metastatic cancer. The first clinical indication for Radspherin® will be treatment of peritoneal carcinomatosis originating from ovarian cancer. Peritoneal carcinomatosis is one of the most serious complications of gastrointestinal and gynecological malignancies. 

About Oncoinvent
Oncoinvent AS is a privately held Norwegian company based in Oslo, Norway. The company is committed to developing new innovative products in order to provide better treatment options to cancer patients.
The company's founders started Oncoinvent in 2010 with a view to designing better cancer treatments by applying known physical and chemical principles of selected novel materials in new ways in order to maximize their medical benefit while minimizing potential safety concerns. This approach has allowed the company to develop a rich development pipeline and to explore multiple technological avenues before selecting a lead product candidate for preclinical testing.

For further information, please contact:
Jan A. Alfheim, Chief Executive Officer
Cell: +47 46 44 00 45
Email: Alfheim@oncoinvent.com

IR enquiries:
Ole Peter Nordby, Acting Chief Financial Officer 
Cell: +47 41 28 71 79 
Email: nordby@oncoinvent.com
 

Read more

Less...

01.25.2017

Oncoinvent is on the move!

Oncoinvent announced today that will be moving operations from its current facilities at Kjelsåsveien 168B to a new location at Gullhaugveien 7 in Nydalen, Oslo in April. The move will provide the company with a larger office space as well as space for a new production and lab facililties.

Download

Jan A. Alfheim, Oncoinvent’s CEO commented: “We are looking forward to moving into our new offices. The space in new facilities will allow the company to expand its research laboratory operations and to design a modern and efficient production facility for clinical supplies of our lead compound Radspherin®. We are grateful for the assistance of NAI FirstPartners in finding such well suited facilities for our needs.”

About Oncoinvent
Oncoinvent AS is a privately held Norwegian company based in Oslo, Norway. The company is committed to developing new innovative products in order to provide better treatment options to cancer patients.

The company's founders started Oncoinvent in 2010 with a view to designing better cancer treatments by applying known physical and chemical principles of selected novel materials in new ways in order to maximize their medical benefit while minimizing potential safety concerns. This approach has allowed the company to develop a rich development pipeline and to explore multiple technological avenues before selecting a lead product candidate for preclinical testing.

 

For further information, please contact:
Jan A. Alfheim, Chief Executive Officer
Cell: +47 46 44 00 45
Email: Alfheim@oncoinvent.com

IR enquiries:
Ole Peter Nordby, Acting Chief Financial Officer
Cell: +47 41 28 71 79
Email: nordby@oncoinvent.com

 

 

Read more

Less...

01.18.2017

Oncoinvent patent issues in the USA

Press release: Oncoinvent announced today that US Patent 9,539,346 entitled "Radiotherapeutic particles and suspensions" has issued. The patent relates to a particle or pharmaceutical composition comprising one or more particles, or a suspension of same or different particles comprising a degradable compound and an alpha emitting radionuclide and/or a radionuclide generating alpha emitting daughter. The particles are beneficial for use in the treatment of cancer.

Download

Jan A. Alfheim, Oncoinvent’s CEO commented: "This is a significant milestone in the development of our lead product candidate, Radspherin®. With this first patent we have gained a solid protection of Radspherin® until 2035 in what we believe will be a very significant future market for the product. Our Radspherin® patent applications include claims on composition of matter as well as various medical and medical device applications. The current applications and this issued patent are therefore very broad and cover a wide spectrum of Radspherin® particle variants and applications."

 

 

About Radspherin®
Radspherin® is a novel alpha-emitting radioactive microsphere designed for treatment of metastatic cancers in body cavities. The radium based therapeutic, Radspherin® has shown strong and consistent anticancer activity at doses being essentially non-toxic in preclinical studies. It is anticipated that the product can potentially treat several forms of metastatic cancer. The first clinical indication for Radspherin® will be treatment of peritoneal carcinomatosis originating from ovarian cancer. Peritoneal carcinomatosis is one of the most serious complications of gastrointestinal and gynecological malignancies.

About Oncoinvent
Oncoinvent AS is a privately held Norwegian company based in Oslo, Norway. The company is committed to developing new innovative products in order to provide better treatment options to cancer patients.

The company's founders started Oncoinvent in 2010 with a view to designing better cancer treatments by applying known physical and chemical principles of selected novel materials in new ways in order to maximize their medical benefit while minimizing potential safety concerns. This approach has allowed the company to develop a rich development pipeline and to explore multiple technological avenues before selecting a lead product candidate for preclinical testing.

 

For further information, please contact:
Jan A. Alfheim, Chief Executive Officer
Cell: +47 46 44 00 45
Email: Alfheim@oncoinvent.com

IR enquiries:
Ole Peter Nordby, Acting Chief Financial Officer
Cell: +47 41 28 71 79
Email: nordby@oncoinvent.com

 

 

Read more

Less...

12.10.2016

DnB Healthcare Prize 2016

Press release: Oncoinvent selected to present as a finalist in DnB Healthcare Prize 2016 competition.

Download

For the second year in a row, the DNB Healthcare Prize will be presented on the 15th of December during the the 7th annual DnB Healthcare Conference. The competition is for companies in an early growth phase.

The winner of the completion will be awarded NOK 1 million.

The companies selected for the DNB Healthcare Prize 2016 final competition include:

  1. SpinChip Diagnostics AS
  2. Vectron Biosolutions AS
  3. Otivio AS
  4. Prediktor Medical AS
  5. EpiGuard AS
  6. Oncoinvent AS

Read more

Less...

09.07.2016

New Chief Executive Officer

The 1st of September 2016, Jan A. Alfheim entered the position as Chief Executive Officer (CEO) of Oncoinvent AS. Jan A. Alfheim comes from the position Chief Operation Officer (COO) in Nordic Nanovector ASA, where he until 2014 was responsible for the company’s leadership as CEO.

Tina B. Bønsdorff enters the position as Chief Scientific Officer (CSO) of Oncoinvent and Ole Peter Nordby has been appointed acting Chief Financial Officer (CFO).

Read more

Less...

08.12.2016

New board members at Oncoinvent as

The extraordinary General Assembly of Oncoinvent convened at July 28th unanimously decided to elect Ludvik Sandnes and Jónas Einarsson as new members of the Board of Directors.

Download

Ludvik Sandnes has more than 40 years of experience from international corporate finance, asset management and investment banking from Norfund, The Royal Bank of Scotland, BDO Noraudit, PwC Financial Advisors, Christiania Bank, UNI Storebrand, Orkla Borregaard, Den Norske Creditbank and Statoil. Current board positions include: Nordic Nanovector (chairman). Oslo Cancer Cluster, IC-T AS, Pre Diagnostics AS, Pioner Fonds AS and Godthaab Helse og Rehabilitering. He has a Bachelor of Commerce and a degree as Certified European Financial Analyst (AFA) from the Norwegian School of Economics and Business Administration, NHH.

Jónas Einarsson is Chief Executive Officer of the Radium Hospital Research Foundation (RF). RF is an experienced pre-seed investor and project developer focused on cancer. Einarsson was one of the initiators behind Oslo Cancer Cluster and the Oslo Cancer Cluster Innovation Park. Jónas Einarsson serves on the board of Targovax (chairman), Ultimovacs and Biomolex.

The General Assembly further released Dr. Øyvind Bruland from his duties at the Board. Bruland will continue to serve as key member of the team at Oncoinvent and enter the position as CMO. As such he will be leading the ongoing preparations for the first clinical trial with Oncoinvent’s lead product candidate Radspherin®.

The extraordinary general assembly also approved the private placement of 34 400 new shares. The placement completes the oversubscribed share issue of May 2016. The total number of shares after this placement will be 775 100, pending for registration in The Register of Business Enterprises.

Read more

Less...

05.20.2016

15 million in a private placement

Oncoinvent AS has successfully completed a private placement. The share offering was directed towards Oncoinvent’s existing shareholders and a limited number of private investors. The issue was oversubscribed and will provide NOK 15 mill. to Oncoinvent, net of transaction costs.

Download

The proceeds will be used to build manufacturing capacity for the clinical development program of the company’s lead compound, a new alpha-therapeutic designed for local treatment of micrometastases. Oncoinvent will further use the funds made available through the transaction to expand its activities and acquire the additional human resources required for preparations of its first clinical trial.

A total of 48 investors participated in the issue. The total number of shares after the Board of Directors allocated new shares at its meeting at May 19th will be 740 700, pending for registration in The Register of Business Enterprises.

Read more

Less...

Subscribe